Trials / Completed
CompletedNCT00727727
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
Stabilization on, or Change-Over to the Non-Ergot Dopamine Agonist Piribedil in Patients With Morbus Parkinson - a Post Marketing Surveillance Study in Private Practices.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 750 (estimated)
- Sponsor
- Desitin Arzneimittel GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson. Neurologists in private practices in Germany should document the safety and course of the disease/change of parkinsonian symptoms during stabilisation on, or change over from other dopamine agonist treatment under routine conditions. Piribedil should be prescribed according to its marketing authorisation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Piribedil |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-08-04
- Last updated
- 2009-02-25
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00727727. Inclusion in this directory is not an endorsement.